Retrospective analysis of the ACCENT 1 (a Crohn’s disease clinical trial evaluating infliximab in a new long-term treatment regimen) trial has also demonstrated durable sustained response through to week 54 in CD patients under IFX, achieving both satisfactory TCs at week 14 (≥3.5 μg/m) and a ≥60% decrease in CRP (C-reactive protein) [53]. Here, CRP is linked to Crohn disease.